Why the study?
CKD-MBD may have overlooked detrimental effects on potentially modifiable components of arterial stiffness beyond vascular calcification.
Can intervening on CKD-MBD biomarkers reverse arterial stiffness in patients with chronic kidney disease?
Can intervening on CKD-MBD biomarkers reverse arterial stiffness in patients with chronic kidney disease?
Interventions targeting CKD-MBD biomarkers have limited and mixed effects on reversing arterial stiffness in CKD patients, with higher calcium potentially worsening it.
No takes yet. Share an insight, caveat, or question.
Non-calcific contributors to arterial stiffness in CKD warrant attention; leaves open mechanistic studies to identify modifiable targets.
Marc Vervloet (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: